Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles

Executive Summary

Sponsors and FDA also will have to work through issues related to companion diagnostics to prevent treatments designated under the FDASIA’s new expedited development pathway from being delayed. Harmonization with foreign regulators is essential to making the pathway work, stakeholders say.

You may also be interested in...



When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes

Clinical data supporting a designation request should come from a product under development, not from a study using an earlier formulation, CBER reps say. Rolling submissions help ensure that potential manufacturing and facility concerns are identified early.

FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products

FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.

FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products

FDA appears to be establishing new regulatory paradigm – albeit one that is not laid out in statute officially.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS054913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel